World's Best Scientists 2026 revealed!
Award Badge
Medicine
Korea
2026

D-Index & Metrics

Medicine

D-Index
129
Citations
93123
World Ranking
2527
National Ranking
1

Yung-Jue Bang publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Yung-Jue Bang sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 927 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Yung-Jue Bang D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Yung-Jue Bang sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 129 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Medicine in Korea Leader Award
  • 2025 - Research.com Medicine in Korea Leader Award
  • 2023 - Research.com Medicine in Korea Leader Award
  • 2022 - Research.com Medicine in Korea Leader Award

Overview

Yung-Jue Bang is affiliated with Seoul National University in South Korea and has published extensively in the field of medicine, with a particular focus on oncology. Their primary research interests include gastric cancer management, colorectal cancer treatments, cancer immunotherapy, and gastrointestinal tumor research.

Their publication record includes frequent contributions to several key journals in oncology and related fields. Notable publication venues include:

  • Journal of Clinical Oncology (35 publications)
  • Clinical Cancer Research (9 publications)
  • Annals of Oncology (5 publications)
  • The Lancet Oncology (4 publications)
  • Cancer Research and Treatment (4 publications)

Their research encompasses a range of subfields within medicine, highlighting oncology (97 publications), pulmonary and respiratory medicine (70 publications), surgery (23 publications), gastroenterology (16 publications), and cancer research (12 publications).

Main topics explored in their work cover various aspects of cancer research and treatment:

  • Gastric Cancer Management and Outcomes (104 publications)
  • Colorectal Cancer Treatments and Studies (46 publications)
  • Cancer Immunotherapy and Biomarkers (42 publications)
  • HER2/EGFR in Cancer Research (38 publications)
  • Gastrointestinal Tumor Research and Treatment (32 publications)
  • Pancreatic and Hepatic Oncology Research (28 publications)
  • Esophageal Cancer Research and Treatment (24 publications)

Frequent collaborators include:

  • Kohei Shitara (42 joint publications)
  • Hyun Cheol Chung (29 joint publications)
  • Eric Van Cutsem (29 joint publications)
  • Min-Hee Ryu (17 joint publications)
  • Charles S. Fuchs (16 joint publications)

Recent notable papers authored or co-authored by Yung-Jue Bang include:

  • "Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study," published in 2020 in The Lancet Oncology
  • "KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors," published in 2020 in New England Journal of Medicine
  • "Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer," published in 2020 in New England Journal of Medicine
  • "Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer," published in 2020 in JAMA Oncology
  • "Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial," published in 2023 in The Lancet

Best Publications

  • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

    Yung Jue Bang;Eric Van Cutsem;Andrea Feyereislova;Hyun C. Chung

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

    Eric Raymond;Laetitia Dahan;Jean Luc Raoul;Yung Jue Bang

  • Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

    Aurelien Marabelle;Dung T. Le;Paolo A. Ascierto;Anna Maria Di Giacomo

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

    Aurélien Marabelle;Marwan Fakih;Juanita Lopez;Manisha Shah

  • Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge

  • Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

    Yung Jue Bang;Young Woo Kim;Han Kwang Yang;Hyun Cheol Chung

  • Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

    Charles S. Fuchs;Toshihiko Doi;Raymond W. Jang;Raymond W. Jang;Kei Muro

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.

    David S. Hong;Marwan G. Fakih;John H. Strickler;Jayesh Desai

  • Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

    Kohei Shitara;Mustafa Özgüroğlu;Yung-Jue Bang;Maria Di Bartolomeo

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

    Kei Muro;Hyun Cheol Chung;Veena Shankaran;Ravit Geva

  • Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.

    Sung Hoon Noh;Sook Ryun Park;Han Kwang Yang;Hyun Cheol Chung

  • Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

    Sae-Won Han;Tae-You Kim;Pil Gyu Hwang;Soohyun Jeong

  • Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies.

    Tae You Kim;Dong-Wan Kim;Jae-Yong Chung;Sang Goo Shin

  • Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

    Kohei Shitara;Yung-Jue Bang;Satoru Iwasa;Naotoshi Sugimoto

  • T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

    Patrick A. Ott;Yung Jue Bang;Sarina A. Piha-Paul;Albiruni R. Abdul Razak

  • Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

    Kohei Shitara;Eric Van Cutsem;Yung Jue Bang;Charles Fuchs

  • HER2-targeted therapies — a role beyond breast cancer

    Do Youn Oh;Yung Jue Bang

Frequent Co-Authors

Seock-Ah Im
Seock-Ah Im Seoul National University Hospital
Dae Seog Heo
Dae Seog Heo Seoul National University Hospital
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Se-Hoon Lee
Se-Hoon Lee Sungkyunkwan University
Hyun Cheol Chung
Hyun Cheol Chung Yonsei University
Woo Ho Kim
Woo Ho Kim Seoul National University
Yoon-Koo Kang
Yoon-Koo Kang Asan Medical Center
Kohei Shitara
Kohei Shitara Yahoo (United Kingdom)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative pathways in healthcare is increasingly popular for those interested in medicine. Many students are seeking flexible and affordable online options to advance their education and careers in nursing and allied health fields.

For registered nurses aiming to earn a bachelor's degree, the cheapest rn to bsn programs offer a budget-friendly and convenient solution. Those looking to progress further in their careers may consider pursuing doctoral education; the cheapest phd nursing programs give aspiring nurse leaders an accessible path to achieving their goals.

Individuals with a non-nursing bachelor's degree can also pivot into the field through the non nursing bachelor's to msn online pathway, streamlining their transition into advanced nursing roles. If you're just getting started, consider online adn programs that offer entry-level access to a nursing career with less competitive admissions criteria.

These flexible options allow more students to gain qualifications that open doors in the health sector, making it easier and more affordable to pursue medical and healthcare careers.

Best Scientists Citing Yung-Jue Bang

Trending Scientists

Recently Published Articles